Corporate Profile

Founded in 2015 after more than a decade of research, ProKidney is a pioneer in the treatment of chronic kidney disease (CKD). Our lead product candidate, REACT™ (Renal Autologous Cell Therapy) is a first-of-its-kind disease modifying cell therapy made from a patient’s own renal cells. REACT™ has the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function, as measured by estimated glomerular filtration rate (eGFR). REACT™ has been studied in multiple clinical trials to-date, and a Phase 3 registrational program was initiated in January 2022. REACT™ received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA in 2021.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Events

SEC Filings

Official notification to shareholders of matters to be brought to a vote ("Proxy")

DEF 14A

An annual report to security holders

ARS

Statement of changes in beneficial ownership of securities

4